Shin Yup Lee

List of Publications by Year
in descending order

88 papers	1,037 citations	516561 16 h-index	526166 27 g-index
90 all docs	90 docs citations	90 times ranked	1992 citing authors

#	Article	IF	Citations
1	Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers. Journal of Thoracic Oncology, 2010, 5, 1734-1740.	0.5	90
2	The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea. Diabetes and Metabolism Journal, 2020, 44, 602.	1.8	83
3	p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Reports, 2019, 28, 1860-1878.e9.	2.9	68
4	Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. Gene, 2017, 599, 28-35.	1.0	47
5	Clinical Significance of Timing of Intubation in Critically Ill Patients with COVID-19: A Multi-Center Retrospective Study. Journal of Clinical Medicine, 2020, 9, 2847.	1.0	43
6	Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer, 2013, 82, 330-339.	0.9	38
7	Putative functional variants of XRCC1 identified by RegulomeDB were not associated with lung cancer risk in a Korean population. Cancer Genetics, 2015, 208, 19-24.	0.2	33
8	CD5L as an Extracellular Vesicle-Derived Biomarker for Liquid Biopsy of Lung Cancer. Diagnostics, 2021, 11, 620.	1.3	33
9	Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer. Journal of Cancer, 2020, 11, 5503-5510.	1.2	32
10	Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery. Oncotarget, 2015, 6, 24522-24532.	0.8	24
11	Replication of the results of genome-wide and candidate gene association studies on telomere length in a Korean population. Korean Journal of Internal Medicine, 2015, 30, 719-726.	0.7	24
12	TERT Polymorphism rs2853669 Influences on Lung Cancer Risk in the Korean Population. Journal of Korean Medical Science, 2015, 30, 1423.	1.1	23
13	Clinical implication of minimal presence of solid or micropapillary subtype in early-stage lung adenocarcinoma. Thoracic Cancer, 2021, 12, 235-244.	0.8	23
14	Functional intronic variant of <i><scp>SLC</scp>5A10</i> affects <i><scp>DRG</scp>2</i> expression and survival outcomes of early-stage non-small-cell lung cancer. Cancer Science, 2018, 109, 3902-3909.	1.7	22
15	Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung Cancer, 2021, 162, 9-15.	0.9	18
16	Clinical relevance of ground glass opacity in 105 patients with miliary tuberculosis. Respiratory Medicine, 2014, 108, 924-930.	1.3	17
17	The influence of <i>TP53</i> mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations. Molecular Carcinogenesis, 2015, 54, 93-101.	1.3	17
18	The pri-let-7a-2 rs1143770C>T is associated with prognosis of surgically resected non-small cell lung cancer. Gene, 2016, 577, 148-152.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Crucial role of temporary airborne infection isolation rooms in an intensive care unit: containing the COVID-19 outbreak in South Korea. Critical Care, 2020, 24, 238.	2.5	17
20	Prevalence of Chronic Obstructive Pulmonary Disease in Korea: The Result of Forth Korean National Health and Nutrition Examination Survey. Tuberculosis and Respiratory Diseases, 2011, 71, 328.	0.7	15
21	Pleural fluid adenosine deaminase/serum C-reactive protein ratio for the differentiation of tuberculous and parapneumonic effusions with neutrophilic predominance and high adenosine deaminase levels. Infection, 2017, 45, 59-65.	2.3	15
22	*RACK1* is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer. Oncotarget, 2015, 6, 4451-4466.	0.8	15
23	Importance of CT image normalization in radiomics analysis: prediction of 3-year recurrence-free survival in non-small cell lung cancer. European Radiology, 2022, 32, 8716-8725.	2.3	14
24	Comparison of Early and Late Tuberculosis Deaths in Korea. Journal of Korean Medical Science, 2017, 32, 700.	1.1	13
25	Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea. Cancer Medicine, 2021, 10, 5809-5822.	1.3	13
26	Differential diagnosis between lymphoma-associated malignant pleural effusion and tuberculous pleural effusion. Annals of Translational Medicine, 2019, 7, 373-373.	0.7	13
27	Predictive Factors and Treatment Outcomes of Tuberculous Pleural Effusion in Patients With Cancer and Pleural Effusion. American Journal of the Medical Sciences, 2017, 354, 125-130.	0.4	12
28	Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection. Yonsei Medical Journal, 2020, 61, 826.	0.9	12
29	A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection. PLoS ONE, 2015, 10, e0140216.	1.1	11
30	A genetic variation in microRNA target site of *ETS2* is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. Oncotarget, 2016, 7, 15948-15958.	0.8	11
31	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Archives of Pharmacal Research, 2022, 45, 263-279.	2.7	11
32	Mycobacterial load affects adenosine deaminase 2 levels of tuberculous pleural effusion. Journal of Infection, 2015, 71, 488-491.	1.7	9
33	Intronic variant of *EGFR* is associated with GBAS expression and survival outcome of early‐stage non‐small cell lung cancer. Thoracic Cancer, 2018, 9, 916-923.	0.8	9
34	Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer. Annals of Surgical Oncology, 2018, 25, 3396-3403.	0.7	8
35	Effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer. Cancer Genetics, 2017, 212-213, 8-12.	0.2	7
36	Usefulness of serum lactate dehydrogenase/pleural fluid adenosine deaminase ratio for differentiating Mycoplasma pneumoniae parapneumonic effusion and tuberculous pleural effusion. Journal of Infection, 2017, 75, 581-583.	1.7	7

#	Article	IF	Citations
37	Comparison of clinical manifestations and treatment outcome according to age groups in adult patients with miliary tuberculosis. Journal of Thoracic Disease, 2018, 10, 2881-2889.	0.6	7
38	Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients. Thoracic Cancer, 2020, 11, 19-28.	0.8	7
39	Clinical features and prognostic factors of critically ill patients with COVID-19 in Daegu, South Korea. Medicine (United States), 2021, 100, e24437.	0.4	7
40	Comparison of short-term mortality between mechanically ventilated patients with COVID-19 and influenza in a setting of sustainable healthcare system. Journal of Infection, 2020, 81, e76-e78.	1.7	7
41	Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer. Oncotarget, 2017, 8, 61777-61785.	0.8	7
42	Laboratory and radiological discrimination between tuberculous and malignant pleural effusions with high adenosine deaminase levels. Korean Journal of Internal Medicine, 2022, 37, 137-145.	0.7	7
43	Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea. Translational Lung Cancer Research, 2021, 10, 4353-4367.	1.3	7
44	The Different Effect of *VEGF* Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology. Journal of Korean Medical Science, 2016, 31, 1735.	1.1	6
45	Association between polymorphisms in microRNA target sites and survival in early-stage non-small cell lung cancer. Thoracic Cancer, 2017, 8, 682-686.	0.8	6
46	Different characteristics of tuberculous pleural effusion according to pleural fluid cellular predominance and loculation. Journal of Thoracic Disease, 2016, 8, 1935-1942.	0.6	5
47	Polymorphisms in cancer-related pathway genes and lung cancer. European Respiratory Journal, 2016, 48, 1184-1191.	3.1	5
48	Neutrophilic Loculated Tuberculous Pleural Effusion: Incidence, Characteristics and Differentiation From Complicated Parapneumonic Effusion. American Journal of the Medical Sciences, 2016, 351, 153-159.	0.4	5
49	Glucose transporter 3 gene variant is associated with survival outcome of patients with non-small cell lung cancer after surgical resection. Gene, 2019, 703, 58-64.	1.0	5
50	*TSC2* genetic variant and prognosis in non-small cell lung cancer after curative surgery. Thoracic Cancer, 2019, 10, 335-340.	0.8	5
51	Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer. Oncology, 2020, 98, 468-477.	0.9	5
52	Genetic variants in histone modification regions are associated with the prognosis of lung adenocarcinoma. Scientific Reports, 2021, 11, 21520.	1.6	5
53	Comparison of exogenous and endogenous lipoid pneumonia: the relevance to bronchial anthracofibrosis. Journal of Thoracic Disease, 2018, 10, 2461-2466.	0.6	4
54	Genetic Variant of Notch Regulator DTX1 Predicts Survival After Lung Cancer Surgery. Annals of Surgical Oncology, 2019, 26, 3756-3764.	0.7	4

#	Article	IF	Citations
55	Etiological Distribution and Morphological Patterns of Granulomatous Pleurisy in a Tuberculosis-prevalent Country. Journal of Korean Medical Science, 2021, 36, e10.	1.1	4
56	First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. Anticancer Research, 2022, 42, 1615-1622.	0.5	4
57	Clinical outcomes of hyperprogression based on volumetry in non‑small cell lung cancer after immune checkpoint inhibitor treatment. Thoracic Cancer, 2022, 13, 2170-2179.	0.8	4
58	Replication of results of a genome-wide association study on lung cancer survival in a Korean population. Cancer Genetics, 2014, 207, 35-39.e2.	0.2	3
59	Development of a prognosis‑prediction model incorporating genetic polymorphism with pathologic stage in stage I non‑small cell lung cancer: <scp>A</scp> multicenter study. Thoracic Cancer, 2017, 8, 251-259.	0.8	3
60	Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer. Gene, 2018, 646, 56-63.	1.0	3
61	An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer. Cancer Genetics, 2018, 228-229, 73-82.	0.2	3
62	Characteristics and survival impact of polymorphonuclear leucocyte‑predominant malignant pleural effusions secondary to lung cancer. Clinical Respiratory Journal, 2020, 14, 772-779.	0.6	3
63	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2459-2469.	1.2	3
64	Clinical impact of rebiopsy among patients with epidermal growth factor receptor‑mutant lung adenocarcinoma in a real‑world clinical setting. Thoracic Cancer, 2021, 12, 890-898.	0.8	3
65	Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome. Scientific Reports, 2021, 11, 1794.	1.6	3
66	Prognostic implication of PD‑L1 polymorphisms in non‑small cell lung cancer treated with radiotherapy. Cancer Medicine, 2021, 10, 8071-8078.	1.3	3
67	A case of paraneoplastic neurological syndrome expressing dual antineuronal antibodies: Anti-hu and recoverin. Annals of Indian Academy of Neurology, 2020, 23, 133.	0.2	3
68	Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. Journal of Lung Cancer, 2011, 10, 1.	0.2	2
69	GLUT1 Variants for Predicting Prognosis After Surgery in Non-small Cell Lung Cancer. Annals of Surgical Oncology, 2018, 25, 948-949.	0.7	2
70	Effect of genetic variation in Notch regulator DTX1 on SCLC prognosis compared with the effect on NSCLC prongosis. Thoracic Cancer, 2020, 11, 2698-2703.	0.8	2
71	Genetic Variants in One-Carbon Metabolism Pathway Predict Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer. Oncology, 2020, 98, 897-904.	0.9	2
72	Comparison of biochemical parameters and chemokine levels in pleural fluid between patients with anergic and non-anergic tuberculous pleural effusion. Tuberculosis, 2020, 123, 101940.	0.8	2

#	Article	IF	Citations
73	Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA : Liquid‐Lung‐A. Thoracic Cancer, 2021, 12, 444-452.	0.8	2
74	Prognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy. Thoracic Cancer, 2021, 12, 874-879.	0.8	2
75	Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non–Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 356-360.	0.6	2
76	Idiopathic Pleural Effusions: Characteristics and Discrimination From Cytology-Negative Malignant Pleural Effusions. American Journal of the Medical Sciences, 2020, 360, 236-242.	0.4	2
77	A single nucleotide polymorphism rs12898 is associated with primary hepatic cancer in a Chinese population. International Journal of Clinical and Experimental Pathology, 2019, 12, 3063-3069.	0.5	2
78	Multicenter real‐world data of patients harboring rare mutations other than <scp>EGFR</scp> or <scp>ALK</scp> in advanced or metastatic non‐small cell lung cancer. Thoracic Cancer, 2022, 13, 380-385.	0.8	2
79	A Case of Metastatic Endobronchial Melanoma from an Unknown Primary Site. Tuberculosis and Respiratory Diseases, 2012, 72, 169.	0.7	1
80	Genetic Variants in the Wnt Signaling Pathway Are Not Associated with Survival Outcome of Non-Small Cell Lung Cancer in a Korean Population. Journal of Korean Medical Science, 2016, 31, 463.	1.1	1
81	Genetic Polymorphisms in Activating Transcription Factor 3 Binding Site and the Prognosis of Early-Stage Non-Small Cell Lung Cancer. Oncology, 2021, 99, 336-344.	0.9	1
82	Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene <i>BRD3</i> is associated with poorer survival outcome in NSCLC. Molecular Oncology, 2022, 16, 750-763.	2.1	1
83	The Relationship between<i>MDR1</i>Polymorphisms and the Response to Etoposide/Cisplatin Combination Chemotherapy in Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2005, 58, 135.	0.7	0
84	Detection of Deep Vein Thrombosis by Follow-up Indirect Computed Tomography Venography after Pulmonary Embolism. Tuberculosis and Respiratory Diseases, 2018, 81, 49.	0.7	0
85	The role of CECR1 in the immune-modulatory effects of butyrate and correlation between ADA2 and M1/M2 chemokines in tuberculous pleural effusion. International Immunopharmacology, 2021, 96, 107635.	1.7	0
86	Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1291-1302.	0.4	0
87	Distribution of Mediastinal Lymph Node Enlargement in Non-Small-Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2004, 56, 646.	0.2	0
88	Post-treatment change in Mycobacterium tuberculosis antigen-stimulated tumor necrosis factor-alpha release in patients with active tuberculosis. Journal of Thoracic Disease, 2015, 7, 903-7.	0.6	0